Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model

IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we investigated the combination of anti-PD-1 and oncolytic measles vaccine in an imm...

Full description

Bibliographic Details
Main Authors: Rūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, Chin Leng Tan, Theresa E. Schäfer, Na Kang, Claudia R. Ball, Jonas Leichsenring, Albrecht Stenzinger, Lars Kaderali, Dirk Jäger, Guy Ungerechts, Christine E. Engeland
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
immune checkpoint
PD-1
oncolytic virus
measles vaccine
PDAC
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1096162/full

Similar Items

Similar Items